Science

Mar 22, 2025, 09:11

Myeloma Paper of the Day, March 22nd, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Real-world analysis of bortezomib-dex-rituximab in patients with Waldenström macroglobulinaemia finds ORR 88%, CR 6%, VGPR 24%, median EFS 33 months, no impact of MYD88 L265P mutation or double mutation MYD88/CXCR4 on OS or EFS.”

“Bortezomib, Rituximab and Dexamethasone Regimen (BDR) in Waldenström Macroglobulinaemia: A Retrospective Real-World Analysis”

Authors: Thomas Hueso, Grégory Lazarian, Paul Chauvet, Adrien Chauchet, Ramy Rahmé, Sabine Brechignac, Vincent Lévy, Salomon Manier, Damien Roos-Weil, David Ghez, Claude Gardin, Fanny Baran-Marszak, Eric Durot, Pierre Morel, Thorsten Braun.

More posts featuring Robert Orlowski.

Adrien Chauchet Bortezomib cancer Claude Gardin dexamethasone Eric Durot Fanny Baran-Marszak Grégory Lazarian Myeloma Paper of the Day OncoDaily Oncology Paul Chauvet Pierre Morel Ramy Rahmé Rituximab Robert Orlowski Thomas Hueso Thorsten Braun Waldenstrom macroglobulinaemia

FDA approval: Pembrolizumab for HER2 positive gastric or GEJ adenocarcinoma expressing PD-L1 (CPS ≥1): KEYNOTE-811 Trial

Changing the Future of Adolescent and Young Adult Cancer Care

OncoDaily Launches New Social Channel on Telegram – @OncoDaily

In Memory of Chadwick Boseman and His Colon Cancer Battle

Groundbreaking Canadian Cancer Society-funded research aims to reshape the future of advanced cancer